ASB9
Ankyrin repeat and SOCS box protein 9
Also known as: ASB9_HUMAN, DKFZP564L0862, FLJ20636, MGC4954
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96DX5
- Gene
- ASB9
- Ensembl
- ENSG00000102048
- Chromosome
- X
- Canonical length
- 294 aa
- Protein class
- Predicted intracellular proteins
OverviewNCBI Gene
This gene encodes a member of the ankyrin repeat and suppressor of cytokine signaling (SOCS) box protein family. Members of this family can interact with the elongin B-C adapter complex via their SOCS box domain and further complex with the cullin and ring box proteins to form E3 ubiquitin ligase complexes. They may function to mediate the substrate-recognition of the E3 ubiquitin ligases. A transcribed pseudogene of this gene has been identified on chromosome 15. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2009]
Canonical amino-acid sequenceUniProt
294 residues, UniProt reviewed canonical sequence.
>Q96DX5|ASB9
1 MDGKQGGMDG SKPAGPRDFP GIRLLSNPLM GDAVSDWSPM HEAAIHGHQL SLRNLISQGW
61 AVNIITADHV SPLHEACLGG HLSCVKILLK HGAQVNGVTA DWHTPLFNAC VSGSWDCVNL
121 LLQHGASVQP ESDLASPIHE AARRGHVECV NSLIAYGGNI DHKISHLGTP LYLACENQQR
181 ACVKKLLESG ADVNQGKGQD SPLHAVARTA SEELACLLMD FGADTQAKNA EGKRPVELVP
241 PESPLAQLFL EREGPPSLMQ LCRLRIRKCF GIQQHHKITK LVLPEDLKQF LLHLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ASB9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.29
- Highest tissue expression
- 24 nTPM
Expression across tissuesHPA
Tissue
- testis: 24 nTPM
- liver: 16 nTPM
- kidney: 16 nTPM
- spleen: 11 nTPM
- pancreas: 9.1 nTPM
- stomach: 3.8 nTPM
Single-cell type
- undifferentiated spermatogonia: 161 nCPM
- differentiating spermatogonia: 140 nCPM
- sertoli cells: 41 nCPM
- parietal cells: 30 nCPM
- renal collecting duct intercalated cells: 29 nCPM
- melanocytes: 23 nCPM
Immune cell
- myeloid DC: 1.6 nTPM
- naive CD4 T-cell: 1.2 nTPM
- MAIT T-cell: 0.7 nTPM
- classical monocyte: 0.6 nTPM
- basophil: 0.4 nTPM
- naive CD8 T-cell: 0.3 nTPM
Brain region
- medulla oblongata: 2.6 nTPM
- cerebellum: 2.3 nTPM
- pons: 2.1 nTPM
- amygdala: 2 nTPM
- cerebral cortex: 1.9 nTPM
- choroid plexus: 1.9 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.58
- gnomAD pLI
- 0.7
- gnomAD missense Z
- 0.99
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- intracellular signal transduction
- positive regulation of protein catabolic process
- proteasome-mediated ubiquitin-dependent protein catabolic process
- protein ubiquitination
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ASB9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ASB9 as an antibody target. Whether an autoantibody or antibody against ASB9 could matter depends on whether native ASB9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ASB9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ASB9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...